Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: An atelocollagen according to an embodiment is characterized in that, when analyzed by high-performance liquid chromatography (HPLC), a peak area (S?) for a ? chain is larger than a second peak area for an ? chain (S?2) so that, when a physiologically active material is loaded therein, the atelocollagen may decrease rapid initial release of the physiologically active material or may control reduction in effects of the physiologically active material due to too slow initial release. Further, the atelocollagen of the present invention may exhibit excellent cancer metastasis inhibitory effects.

Abstract: One aspect according to the present disclosure relates to a novel nucleic acid ligand which is a new class of nucleic acid compound, the existence of which was considered impossible in the prior art. The novel nucleic acid ligand has specific binding affinity with respect to at least two different targets having three-dimensional structures, and the binding sites for the at least two targets are formed in or from a single nucleic acid ligand. The novel nucleic acid ligand according the present disclosure can simultaneously solve several problems of existing aptamers that the prior art could not solve. One aspect according to the present disclosure relates to a novel screening method for identifying the above-mentioned novel nucleic acid ligand. The novel screening method uses a step for sequentially contacting at least two different targets having three-dimensional structures to screen a novel nucleic acid ligand that was previously thought impossible.

Abstract: A drug delivery system includes an atelocollagen-[aptamer-drug] complex which is prepared by mixing an aptamer-drug conjugate comprised of an aptamer and a drug attached to the aptamer with an atelocollagen dispersion. The aptamer is selected from the group consisting of AS1411, CRO, and ERBB2, and the drug is selected from the group consisting of Gemcitabine, Doxorubicin, and siRNA. An anticancer composition including the drug delivery system can compensate for shortcomings of existing anticancer agents and anticancer therapies.